The Efficacy and Safety of a Selective Estrogen Receptor Beta Agonist (LY500307) for Negative Symptoms and Cognitive Impairment Associated With Schizophrenia
Phase of Trial: Phase II
Latest Information Update: 17 Mar 2017
At a glance
- Drugs Erteberel (Primary) ; Antipsychotics
- Indications Schizophrenia
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 10 Mar 2017 Planned End Date changed from 1 Jun 2017 to 1 Jul 2017.
- 10 Mar 2017 Planned primary completion date changed from 1 Apr 2017 to 1 May 2017.